Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why
60-Word AI Digest
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.
Key Takeaways
- Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside.
- The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.
- Full details and original dispatch available below.
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.
Original Publisher Attribution
This summary was curated from Economic Times.